View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 6, 2020

Coronavirus company news summary

By Allie Nawrat

6 April 2020 

Researchers from the Biomedicine Discovery Institute (BDI) at Monash University,  Australia, have found that an anti-parasitic drug called Ivermectin could kill the novel coronavirus, SARS-CoV-2, within 48 hours in a laboratory setting. Additional tests and clinical trials in humans are required to validate the drug’s safety and effectiveness as a potential Covid-19 treatment. Read the full story here.

GlaxoSmithKline (GSK) has agreed to offer its pandemic adjuvant system to Xiamen Innovax Biotech for preclinical assessment of a recombinant protein-based vaccine candidate against Covid-19. This vaccine candidate, known as Covid-19 XWG-03, is being developed by Innovax in alliance with Xiamen University. Read the full story here

The UK Government has announced that a large-scale randomised clinical trial of potential Covid-19 treatment led by the University of Oxford is being conducted at more than 130 hospitals across the country; this makes this the world’s largest Covid-19 trial. The trial will assess HIV drugs lopinavir/ritonavir, dexamethasone steroid and anti-malarial hydroxychloroquine in more than 1,000 Covid-19 patients. Read the full story here.

UK-based Izana Bioscience has launched a two-centre compassionate use study of rheumatoid arthritis drug namilumab in patients with rapidly worsening Covid-19 in Bergamo and Milan, Italy. The study will collect data from hospitalised patients and aims to provide treatment before admission to intensive care or need for ventilation. Read the full story here

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy